| Literature DB >> 26082989 |
War War May Zin1,2, Suradet Buttachon1,2, Jamrearn Buaruang3, Luís Gales4,5, José A Pereira6, Madalena M M Pinto2,7, Artur M S Silva8, Anake Kijjoa9,10.
Abstract
A new meroditerpene sartorenol (1), a new natural product takakiamide (2) and a new tryptoquivaline analog (3) were isolated, together with nine known compounds, including aszonapyrone A, chevalone B, aszonalenin, acetylaszonalenin, 3'-(4-oxoquinazolin-3-yl) spiro[1H-indole-3,5'-oxolane]-2,2'-dione, tryptoquivalines L, F and H, and the isocoumarin derivative, 6-hydroxymellein, from the ethyl acetate extract of the culture of the algicolous fungus Neosartorya takakii KUFC 7898. The structures of the new compounds were established based on 1D and 2D NMR spectral analysis, and, in the case of sartorenol (1) and tryptoquivaline U (3), X-ray analysis was used to confirm their structures and to determine the absolute configuration of their stereogenic carbons. Compounds 1, 2 and 3 were evaluated for their antimicrobial activity against Gram-positive and Gram-negative bacteria, and multidrug-resistant isolates from the environment; however, none exhibited antibacterial activity (MIC ˃ 256 mg/mL). The three new compounds did not show any quorum sensing inhibition in the screening protocol based on the pigment production by Chromobacterium violaceum (ATCC 31532).Entities:
Keywords: 6-hydroxymellein; Neosartorya takakii; aszonalenin; aszonapyrone A; chevalone B; meroditerpene; sartorenol; tryptoquivaline U
Mesh:
Substances:
Year: 2015 PMID: 26082989 PMCID: PMC4483656 DOI: 10.3390/md13063776
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1New secondary metabolites isolated from the ethyl acetate extract of the culture of N. takakii KUFC 7898.
1H and 13C NMR (CDCl3, 300.13 MHz and 75.47 MHz) and HMBC assignment for 1.
| Position | δC, Type | δH, ( | COSY | HMBC |
|---|---|---|---|---|
| 1 | 38.2, CH2 | 1.05, m | H-2 | |
| 2 | 23.3, CH2 | 1.65, m | H-1, 3 | |
| 1.33, dd (12.9, 4.2) | H-1, 3 | C-4 | ||
| 3 | 80.8, CH | 4.48, dd (10.9, 4.6) | H-2 | C-1, 4, 21, 22 |
| 4 | 37.8, C | - | ||
| 5 | 55.4, CH | 0.91, dd (12.0, 2.2) | H-6 | |
| 6 | 18.7, CH2 | 1.62, m | H-5 | |
| 1.14, m | ||||
| 7 | 40.5, CH2 | 1.18, dd (12.5, 3.6) | ||
| 1.88, m | ||||
| 8 | 39.8, C | - | ||
| 9 | 59.8, CH | 1.02, dd (12.3, 2.6) | ||
| 10 | 37.4, C | - | ||
| 11 | 23.6, CH2 | 1.70, m | ||
| 12 | 38.0, CH2 | 2.38, m | ||
| 1.92, m | C-14, 25 | |||
| 13 | 147.7, C | - | ||
| 14 | 56.4, CH | 1.59, m | H-15 | |
| 15 | 19.6, CH2 | 1.86, m | H-14, 16 | C-13 |
| 16 | 37.2, CH2 | 2.08, m | H-15 | |
| 17 | 194.7, CO | - | ||
| 18 | 99.9, CH | 5.45, s | C-16, 17, 19, 20 | |
| 19 | 191.1, C | - | ||
| 20 | 24.9, CH3 | 2.05, s | C-18, 19 | |
| 21 | 16.3, CH3 | 0.83, s | C-3, 4, 5, 22 | |
| 22 | 28.0, CH3 | 0.86, s | C-3, 4, 5, 21 | |
| 23 | 16.4, CH3 | 0.84, s | C-1, 5, 9, 10 | |
| 24 | 15.3, CH3 | 0.69, s | C-7, 8, 9, 14 | |
| 25a | 106.4, CH2 | 4.84, brs | C-12, 14 | |
| b | 4.50, brs | C-12, 13, 14 | ||
| 26 | 171.0, CO | - | ||
| 27 | 21.3, CH3 | 2.05, s | C-26 | |
| OH-19 | 15.47, s |
Figure 2Ortep view of sartorenol (1).
Figure 3Proposed biogenesis of sartorenol (1).
1H and 13C NMR (DMSO, 300.13 MHz and 75.47 MHz) and HMBC assignment for 2.
| Position | δC, Type | δH, ( | COSY | HMBC |
|---|---|---|---|---|
| 2 | 127.3, CH | 7.15, s | C-3, 8, 9 | |
| 3 | 108.0, C | - | ||
| 4 | 118.4, CH | 7.54, d (7.8) | H-5 | C-3, 6, 8 |
| 5 | 119.2, CH | 7.08, ddd (7.8, 7.8, 0.7) | H-4, 6 | C-7, 9 |
| 6 | 121.7, CH | 7.20, ddd (7.8, 7.8, 0.7) | H-5, 7 | C-4, 8 |
| 7 | 109.9, CH | 7.31, d (7.8) | H-6 | C-5, 9 |
| 8 | 136.3, C | - | ||
| 9 | 127.9, C | - | ||
| 10 | 22.4, CH2 | 3.57, dd (15.2, 5.5) | H-11 | C-2, 3, 17 |
| 3.26, dd (15.2, 8.3) | H-11 | C-2, 3, 17 | ||
| 11 | 52.4, CH | 4.12, dt (8.3, 5.5) | H-10, NH-12 | |
| 13 | 168.9, CO | - | ||
| 14 | 125.5, C | - | ||
| 15 | 135.7, C | - | ||
| 17 | 172.0, CO | |||
| 18 | 121.0, CH | 7.06, d (8.0) | H-19 | C-14, 20 |
| 19 | 133.1, CH | 7.50, ddd (8.0, 8.0, 1.5) | H-18, 20 | C-15, 21 |
| 20 | 125.2, CH | 7.24, dd (8.0, 8.0) | H-19, 21 | C-14, 18 |
| 21 | 131.4, CH | 7.91, dd (8.0, 1.5) | H-20 | C-13, 19, 15 |
| 1′ | 44.2, CH2 | 4.63, d (6.8) | H-2′ | C-2, 2′, 3′ |
| 2′ | 119.9, CH | 5.35, m | H-1′, 4′, 5′ | |
| 3′ | 136.4, C | - | ||
| 4′ | 25.6, CH3 | 1.74, s | H-1′, 2′ | C-2′, 3′, 5′ |
| 5′ | 18.1, CH3 | 1.80, s | H-1′, 2′ | C-2′, 3′, 5′ |
| NH-12 | 7.03, d (5.5) | H-11 | ||
| NH-16 | 9.03, s | C-11, 14 |
Figure 4Conformations of C-11R stereoisomer of compound 2 obtained by simulation performed with ChemBio3D Ultra 14.0; (a) conformer with H-11 in equatorial position; (b) conformer with H-11 in axial position.
1H and 13C NMR (DMSO, 300.13 MHz and 75.47 MHz) and HMBC assignment for tryptoquivaline U (3).
| Position | δC, Type | δH, ( | COSY | HMBC |
|---|---|---|---|---|
| 2 | 82.0, CH | 5.55, d (8.4) | NH-16 | C-13, 14 |
| 3 | 84.7, C | - | ||
| 4 | 132.0, C | - | ||
| 5 | 125.7, CH | 7.71, d (7.3) | H-6 | C-7, 9 |
| 6 | 125.7, CH | 7.38, ddd (7.5, 7.5, 1.2) | H-5, 7 | C-4, 8 |
| 7 | 131.6, CH | 7.57, ddd (8.1, 7.7, 1.2) | H-6, 8 | C-5, 9 |
| 8 | 116.2, CH | 7.49, d (7.2) | H-7 | C-4, 6 |
| 9 | 139.8, C | - | ||
| 11 | 170.7, CO | - | ||
| 12 | 56.9, CH | 5.58, dd (10.8, 9.1 | H-13 | C-3, 11, 13, 18, 26 |
| 13 | 31.6, CH2 | 2.86, dd (12.9, 9.1) | H-12 | C-2, 4, 11, 12 |
| 3.45, dd (12.9, 11.2) | H-12 | C-2, 3, 4, 12 | ||
| 14 | 176.0, CO | - | ||
| 15 | 64.6, C | - | ||
| 16 | - | 3.76, d (8.4) | H-2 | C-2, 3, 14, 15, 26, 27 |
| 18 | 159.6, CO | - | ||
| 19 | 121.4, C | - | ||
| 20 | 126.1, CH | 8.23, dd (8.0, 1.2) | H-21 | C-18, 22, 24 |
| 21 | 127.6, CH | 7.63, ddd (7.6, 7.6, 1.0) | H-20, 22 | C-19, 23 |
| 22 | 135.0, CH | 7.92, ddd (8.2, 8.2, 1.5) | H-21, 23 | C-20, 24 |
| 23 | 127.3, CH | 7.76, d (7.7) | H-22 | C-19, 21 |
| 24 | 147.5, C | - | ||
| 26 | 147.4, CH | 8.49, s | C-12, 18, 24 | |
| 27 | 26.5, CH3 | 1.45, s | C-14, 15, 28 | |
| 28 | 26.9, CH3 | 1.24, s | C-14, 15, 27 |
Figure 5Ortep view of tryptoquivaline U (3).